Leading the clinical development of
fibrinolysis without bleeding
to change the treatment paradigm for
ischemic stroke and heart attack.
Thrombolytic Science (TSI) is a private, clinical stage, vascular medicine & biotech company.
Current treatment options for patients experiencing a stroke or heart attack are limited and delay the
re-establishment of blood flow.
TSI is dedicated to transforming standards of care, by bringing a simple intravenous biotherapy to the patient, closer to the time of onset.
TSI’s bio-inspired solution is
A low dose, safer, dual thrombolytic Rx
Based on a clinically validated mechanism
To be given on suspicion of a stroke or heart attack
TSI recently completed a Phase 1 clinical study confirming the safety and tolerability of its novel tPA / HisproUK dual regimen.
TSI's dual regimen is currently being tested in two Phase 2 clinical trials, one in ischemic stroke patients, and an another in patients with acute myocardial infarction.
tPA's biological role is limited to degrading the surface of the clot.
With TSI’s regimen, once this occurs, the small amount of tPA used is rapidly cleared from the blood flow. HisproUK, TSI's compound, exclusively targets the now degraded clot and dissolves it.
Should there be no degraded clot, as in the case of stroke mimics or a hemorrhagic stroke, HisproUK will remain safely in its inactive pro enzymatic form before being cleared in minutes from the blood flow.
TSI's thrombolytic regimen could therefore be given safely on simple suspicion of an ischemic stroke, as soon as possible after stroke onset.
Management & Board of Directors
President and Chief Executive Officer,
Director and Co-founder
Chief Scientific Officer, Director and Co-founder
Chairman of the Court,
London School of Hygiene &
Professor of Medicine, Hematology
Adjunct Professor, Neurology,
Harvard Medical School, Former Chief Medical Officer, Chairman & Founder, InfraReDx
1985 Nobel Peace Prize
President & CEO,
Baim Institute for Clinical Research
Professor of Medicine,
Harvard Medical School
Chairman & Founder, PERFUSE
October 30, 2019
September 5, 2018
May 30, 2018
May 24, 2018
December 14, 2017
November 15, 2017
September 18, 2017
VIEW> Tomasi S, Sarmientos P, Giorda G, Gurewich V, Vercelli A. Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke. PLoS One. 2011; 6(7):e21999